MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$82,737K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from exercise of series...
Sales/maturities of marketable s...
Increase in fair value of royalt...
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Proceeds from sale of shares of ...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-15,008
-16,988
9,663
-12,158
Increase in fair value of royalty monetization liability
-872
-
-
-
Change in fair value of royalty monetization liability
-
-
0
0
Noncash consideration received in licensing agreement transaction
733
-
-
-
Unrealized loss on equity investment
0
0
21,118
0
Change in accrued interest and accretion of discount on marketable securities
-500
-287
-262
-111
Stock-based compensation expense
1,431
1,046
1,195
1,109
Depreciation and amortization expense
16
35
17
16
Noncash operating lease expense
318
312
305
300
Change in lease liability
-355
-349
-342
-337
Prepaid expenses and other current assets
1,775
-110
1,446
-522
Accounts payable
-1,508
3,624
246
-2,240
Accrued expenses
-352
-1,402
2,052
27
Deferred revenue
-718
-
-
0
Net cash used in operating activities
-17,594
-13,899
-10,408
-12,872
Purchase of marketable securities
102,740
4,050
77,062
4,947
Sales/maturities of marketable securities
16,000
10,000
5,000
10,000
Purchases of property and equipment
-
-
0
0
Software development and other costs
-
-
0
0
Net cash (used in) provided by investing activities
-86,740
5,950
-72,062
5,053
Proceeds from sale of shares of common stock and pre-funded warrants, net of expenses
-3,619
59,803
75,116
-
Proceeds from exercise of series a warrants into shares of common stock and pre-funded warrants, net of expenses
25,212
26,593
-
-
Proceeds from sale of shares of common stock under atm program, net of expenses
1
2,366
-
-
Proceeds from exercise of options and employee stock purchase plan
7
220
63
15
Net cash provided by financing activities
21,601
88,982
75,179
15
Effect of exchange rates on cash, cash equivalents and restricted cash
-4
-122
-167
-
Net decrease in cash, cash equivalents and restricted cash
-
-
-
-7,804
Net (decrease) increase in cash, cash equivalents and restricted cash
-82,737
80,911
-13,148
-
Cash, cash equivalents and restricted cash, at beginning of period
95,995
15,084
22,542
28,232
Cash, cash equivalents and restricted cash, at end of period
13,258
95,995
15,084
22,542
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
series a warrants into...
$25,212K
Proceeds from exercise of
options and employee...
$7K
(-46.15%↓ Y/Y)
Proceeds from sale of
shares of common stock...
$1K
Net cash provided by
financing activities
$21,601K
(166061.54%↑ Y/Y)
Canceled cashflow
$3,619K
Net (decrease)
increase in cash, cash...
-$82,737K
Canceled cashflow
$21,601K
Sales/maturities of marketable
securities
$16,000K
(-40.74%↓ Y/Y)
Stock-based compensation
expense
$1,431K
(-42.83%↓ Y/Y)
Increase in fair value of
royalty monetization...
-$872K
Noncash operating lease
expense
$318K
(-45.36%↓ Y/Y)
Depreciation and
amortization expense
$16K
(-93.33%↓ Y/Y)
Proceeds from sale of
shares of common stock...
-$3,619K
Net cash (used in)
provided by investing...
-$86,740K
(-605.63%↓ Y/Y)
Canceled cashflow
$16,000K
Net cash used in
operating activities
-$17,594K
(-16.87%↓ Y/Y)
Effect of exchange
rates on cash, cash...
-$4K
Canceled cashflow
$2,637K
Purchase of marketable
securities
$102,740K
(943.58%↑ Y/Y)
Net loss
-$15,008K
(-0.60%↓ Y/Y)
Prepaid expenses and
other current assets
$1,775K
(102.16%↑ Y/Y)
Accounts payable
-$1,508K
(-298.42%↓ Y/Y)
Noncash consideration
received in licensing...
$733K
Deferred revenue
-$718K
(-200.00%↓ Y/Y)
Change in accrued
interest and accretion of...
-$500K
(-55.28%↓ Y/Y)
Buy us a coffee
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)